Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31905
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorROMANO, Paschoalina
dc.contributor.authorAGENA, Fabiana
dc.contributor.authorEBNER, Persio de Almeida Rezende
dc.contributor.authorSUMITA, Nairo Massakazu
dc.contributor.authorTRIBONI, Ana Heloisa Kamada
dc.contributor.authorRAMOS, Fernanda
dc.contributor.authorGARCIA, Marcio dos Santos
dc.contributor.authorDUARTE, Nilo Jose Coelho
dc.contributor.authorLEMOS, Francine Brambate Carvalhinho
dc.contributor.authorGALANTE, Nelson Zocoler
dc.contributor.authorDAVID-NETO, Elias
dc.date.accessioned2019-05-30T13:45:16Z
dc.date.available2019-05-30T13:45:16Z
dc.date.issued2019
dc.identifier.citationEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, v.44, n.2, p.189-199, 2019
dc.identifier.issn0378-7966
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31905
dc.description.abstractBackground and ObjectivesElderly patients are increasingly likely to be recipients of transplants. However, the pharmacokinetics of mycophenolic acid (MPA) in this population are yet to be studied in detail. The objective of this study was to assess whether there were differences in MPA pharmacokinetic parameter values between elderly recipients and younger-adult recipients during the 6months immediately following renal transplantation.MethodsIn this analysis, the longitudinal 12-h pharmacokinetics of MPA, administered as enteric-coated mycophenolate sodium (EC-MPS), were evaluated in 44 elderly renal transplant recipients and compared with the corresponding pharmacokinetics of MPA in 31 younger adult recipients. Measurements were performed at 7, 30, 60, 90, and 180days post-transplantation. All patients received tacrolimus and prednisone.ResultsThe elderly patients were 30years older than the younger controls, with a predominance of males and Caucasians. Elderly patients had lower serum albumin than the younger controls during the first 6months after transplantation. The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.310.17 vs 0.300.25L/h/kg). MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 +/- 3.61 vs 5.95 +/- 4.29 mu g<bold>h</bold>/mL per mg/kg for the elderly recipients and the controls).ConclusionsThese data show that the pharmacokinetics of MPA in elderly renal transplant recipients were no different to those of younger-adult recipients in this study population.Clinicaltrials.govp id=""Par5000"">NCT 01631058.eng
dc.description.sponsorshipNovartis Pharma Brazil
dc.language.isoeng
dc.publisherSPRINGER FRANCEeng
dc.relation.ispartofEuropean Journal of Drug Metabolism and Pharmacokinetics
dc.rightsrestrictedAccesseng
dc.subject.otherdrug-metabolismeng
dc.subject.othermofetileng
dc.subject.otherkidneyeng
dc.subject.othertacrolimuseng
dc.subject.otherexposureeng
dc.subject.otherlivereng
dc.subject.otherimmunosuppressioneng
dc.subject.otherpharmacodynamicseng
dc.subject.othermulticentereng
dc.subject.otherpreventioneng
dc.titleLongitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trialeng
dc.typearticleeng
dc.rights.holderCopyright SPRINGER FRANCEeng
dc.identifier.doi10.1007/s13318-018-0506-6
dc.identifier.pmid30229398
dc.subject.wosPharmacology & Pharmacyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalRAMOS, Fernanda:Univ Sao Paulo, Sch Med, Renal Transplantat Serv, Div Urol,Hosp Clin, Av Dr Eneas de Carvalho Aguiar 255, BR-05403900 Sao Paulo, Brazil
hcfmusp.description.beginpage189
hcfmusp.description.endpage199
hcfmusp.description.issue2
hcfmusp.description.volume44
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000461290500005
hcfmusp.origem.id2-s2.0-85053697967
hcfmusp.publisher.cityPARISeng
hcfmusp.publisher.countryFRANCEeng
hcfmusp.relation.referenceAllison AC, 2005, TRANSPLANTATION, V80, pS181, DOI 10.1097/01.tp.0000186390.10150.66eng
hcfmusp.relation.referenceAnantharaju A, 2002, GERONTOLOGY, V48, P343, DOI 10.1159/000065506eng
hcfmusp.relation.reference[Anonymous], 2004, PROP WORK DEF OLD PEeng
hcfmusp.relation.referenceBehrend M, 1999, TRANSPLANTATION, V68, P391eng
hcfmusp.relation.referenceBrunton LL, 2011, PHARMACOL BASIS THEReng
hcfmusp.relation.referenceCho S, 1999, AM J KIDNEY DIS, V34, P296eng
hcfmusp.relation.referenceDanovitch GM, 2005, AM J TRANSPLANT, V5, P904, DOI 10.1111/j.1600-6135.2005.00835.xeng
hcfmusp.relation.referenceDavid-Neto E, 2016, AM J TRANSPLANT, V16, P305eng
hcfmusp.relation.referenceDavid-Neto E, 2001, PEDIATR TRANSPLANT, V5, P302, DOI 10.1034/j.1399-3046.2001.00007.xeng
hcfmusp.relation.referenceDavid-Neto E, 2017, TRANSPLANTATION, V101, P2133, DOI 10.1097/TP.0000000000001549eng
hcfmusp.relation.referenceDavid-Neto E, 2017, TRANSPLANTATION, V101, P1365, DOI 10.1097/TP.0000000000001369eng
hcfmusp.relation.referenceDavid-Neto E, 2012, THER DRUG MONIT, V34, P331, DOI 10.1097/FTD.0b013e31824d6e8eeng
hcfmusp.relation.referenceDu SD, 2013, NUCL MED COMMUN, V34, P893, DOI 10.1097/MNM.0b013e328362e7c7eng
hcfmusp.relation.referenceFiller G, 2006, PEDIATR TRANSPLANT, V10, P707, DOI 10.1111/j.1399-3046.2006.00553.xeng
hcfmusp.relation.referenceGaston R, 2009, AM J TRANSPLANT, V9, P1607, DOI 10.1111/j.1600-6143.2009.02668.xeng
hcfmusp.relation.referenceGinsberg G, 2005, ENVIRON HEALTH PERSP, V113, P1243, DOI 10.1289/ehp.7568eng
hcfmusp.relation.referenceHaubner R, 2013, EUR J NUCL MED MOL I, V40, P1245, DOI 10.1007/s00259-013-2397-8eng
hcfmusp.relation.referenceHolt CD, 1998, BIODRUGS, V10, P373, DOI 10.2165/00063030-199810050-00004eng
hcfmusp.relation.referenceKlotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679eng
hcfmusp.relation.referenceKnight SR, 2008, TRANSPLANTATION, V85, P1675, DOI 10.1097/TP.0b013e3181744199eng
hcfmusp.relation.referenceKofler S, 2009, J HEART LUNG TRANSPL, V28, P605, DOI 10.1016/j.healun.2009.03.006eng
hcfmusp.relation.referenceKovarik JM, 1999, DRUG AGING, V15, P197, DOI 10.2165/00002512-199915030-00003eng
hcfmusp.relation.referenceKROEMER HK, 1992, CLIN PHARMACOKINET, V23, P292, DOI 10.2165/00003088-199223040-00005eng
hcfmusp.relation.referenceLangman LJ, 1996, TRANSPLANTATION, V62, P666, DOI 10.1097/00007890-199609150-00022eng
hcfmusp.relation.referenceLe Meur Y, 2007, AM J TRANSPLANT, V7, P2496, DOI 10.1111/j.1600-6143.2007.01983.xeng
hcfmusp.relation.referenceLorber MI, 2005, TRANSPLANTATION, V80, P244, DOI 10.1097/01.TP.0000164352.65613.24eng
hcfmusp.relation.referenceMeier-Kriesche HU, 2006, AM J TRANSPLANT, V6, P1111, DOI 10.1111/j.1600-6143.2006.01270.xeng
hcfmusp.relation.referenceMiura M, 2008, THER DRUG MONIT, V30, P46, DOI 10.1097/FTD.0b013e31816337b7eng
hcfmusp.relation.referenceMiura M, 2009, EUR J CLIN PHARMACOL, V65, P1047, DOI 10.1007/s00228-009-0721-9eng
hcfmusp.relation.referenceMourad M, 2001, CLIN CHEM, V47, P88eng
hcfmusp.relation.referencePATWARDHAN RV, 1981, GASTROENTEROLOGY, V81, P1006eng
hcfmusp.relation.referencePereira LM, 2006, INTERFERENCE CALCINEeng
hcfmusp.relation.referenceRosenberger J, 2006, TRANSPLANTATION, V81, P1306, DOI 10.1097/01.tp.0000209596.01164.c9eng
hcfmusp.relation.referenceRupprecht K, 2009, J CLIN PHARMACOL, V49, P1196, DOI 10.1177/0091270009344988eng
hcfmusp.relation.referenceSegev DL, 2009, J AM SOC NEPHROL, V20, P621, DOI 10.1681/ASN.2008060591eng
hcfmusp.relation.referenceSELLERS EM, 1979, CLIN PHARMACOL THER, V26, P240eng
hcfmusp.relation.referenceShaw LM, 2003, AM J TRANSPLANT, V3, P534, DOI 10.1034/j.1600-6143.2003.00079.xeng
hcfmusp.relation.referenceSotaniemi EA, 1997, CLIN PHARMACOL THER, V61, P331, DOI 10.1016/S0009-9236(97)90166-1eng
hcfmusp.relation.referenceStaatz CE, 2005, DRUG AGING, V22, P541, DOI 10.2165/00002512-200522070-00001eng
hcfmusp.relation.referenceTang JT, 2017, BRIT J CLIN PHARMACO, V83, P812, DOI 10.1111/bcp.13154eng
hcfmusp.relation.referencevan Gelder T, 2006, THER DRUG MONIT, V28, P145, DOI 10.1097/01.ftd.0000199358.80013.bdeng
hcfmusp.relation.referencevan Gelder T, 1999, TRANSPLANTATION, V68, P261, DOI 10.1097/00007890-199907270-00018eng
hcfmusp.relation.referencevan Gelder T, 2008, TRANSPLANTATION, V86, P1043, DOI 10.1097/TP.Gb013e318186f98aeng
hcfmusp.relation.referenceWang CX, 2007, TRANSPL P, V39, P1392, DOI 10.1016/j.transproceed.2007.02.082eng
hcfmusp.relation.referenceWeber LT, 2002, J AM SOC NEPHROL, V13eng
hcfmusp.relation.referenceWolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303eng
hcfmusp.relation.referenceZeeh J, 2002, GERONTOLOGY, V48, P121, DOI 10.1159/000052829eng
hcfmusp.relation.referenceZoli M, 1999, AGE AGEING, V28, P29, DOI 10.1093/ageing/28.1.29eng
dc.description.indexMEDLINEeng
dc.identifier.eissn2107-0180
hcfmusp.citation.scopus4-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial


Files in This Item:
File Description SizeFormat 
art_ROMANO_Longitudinal_Pharmacokinetics_of_Mycophenolic_Acid_in_Elderly_Renal_2019.PDF
  Restricted Access
publishedVersion (English)875.47 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.